Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
SEK 0.12
(-0.84%)
SEK 0.12
(-0.84%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.25 Million SEK | -24.53% |
| 2022 | 38.13 Million SEK | -14.06% |
| 2021 | 44.37 Million SEK | 266.64% |
| 2020 | 12.1 Million SEK | 81.25% |
| 2019 | 6.67 Million SEK | 76.36% |
| 2018 | 3.78 Million SEK | -99.88% |
| 2017 | 3.03 Billion SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 9.32 Million SEK | -76.41% |
| 2024 Q1 | 7.41 Million SEK | -0.04% |
| 2023 FY | 28.77 Million SEK | -24.53% |
| 2023 Q2 | 8.91 Million SEK | 30.55% |
| 2023 Q1 | 6.82 Million SEK | -28.91% |
| 2023 Q4 | 7.41 Million SEK | 42.0% |
| 2023 Q3 | 5.22 Million SEK | -41.4% |
| 2022 Q3 | 6.84 Million SEK | -45.9% |
| 2022 Q4 | 9.6 Million SEK | 40.34% |
| 2022 Q2 | 12.65 Million SEK | 40.14% |
| 2022 Q1 | 9.02 Million SEK | -39.39% |
| 2022 FY | 38.13 Million SEK | -14.06% |
| 2021 FY | 44.37 Million SEK | 266.64% |
| 2021 Q2 | 11.14 Million SEK | 83.15% |
| 2021 Q4 | 14.89 Million SEK | 21.62% |
| 2021 Q1 | 6.08 Million SEK | 10.2% |
| 2021 Q3 | 12.24 Million SEK | 9.92% |
| 2020 Q1 | 1.59 Million SEK | 0.0% |
| 2020 FY | 12.1 Million SEK | 81.25% |
| 2020 Q4 | 5.52 Million SEK | 96.97% |
| 2020 Q3 | 2.8 Million SEK | 29.35% |
| 2020 Q2 | 2.16 Million SEK | 35.61% |
| 2019 FY | 6.67 Million SEK | 76.36% |
| 2018 FY | 3.78 Million SEK | -99.88% |
| 2017 FY | 3.03 Billion SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 99.521% |
| Camurus AB (publ) | 1.05 Billion SEK | 99.315% |
| Mendus AB (publ) | 129.13 Million SEK | 94.383% |
| Lipum AB (publ) | 37.3 Million SEK | 80.556% |
| NextCell Pharma AB | -576.01 Thousand SEK | 1359.333% |
| Simris Alg AB (publ) | 38.64 Million SEK | 81.228% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 74.391% |
| Active Biotech AB (publ) | 44.8 Million SEK | 83.811% |
| Amniotics AB (publ) | 29.07 Million SEK | 75.048% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | 50.495% |
| BioArctic AB (publ) | 89.62 Million SEK | 91.906% |
| Cantargia AB (publ) | 290.01 Million SEK | 97.499% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 66.869% |
| CombiGene AB (publ) | 44.14 Million SEK | 83.567% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 94.927% |
| Genovis AB (publ.) | 88.19 Million SEK | 91.775% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 93.696% |
| Isofol Medical AB (publ) | 7.26 Million SEK | 0.193% |
| Intervacc AB (publ) | 79.78 Million SEK | 90.908% |
| Kancera AB (publ) | 63.07 Million SEK | 88.5% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -31.437% |
| LIDDS AB (publ) | 27.75 Million SEK | 73.861% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 94.663% |
| OncoZenge AB (publ) | 15.9 Million SEK | 54.392% |
| Saniona AB (publ) | 1.07 Million SEK | -573.538% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 97.744% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 97.972% |
| Xintela AB (publ) | 57.31 Million SEK | 87.344% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 96.008% |
| Ziccum AB (publ) | 27.87 Million SEK | 73.979% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 55.771% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 97.638% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 82.985% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 58.978% |
| Corline Biomedical AB | 30.16 Million SEK | 75.955% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 87.5% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 91.278% |
| Aptahem AB (publ) | 10.01 Million SEK | 27.554% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 94.614% |
| Fluicell AB (publ) | 28.61 Million SEK | 74.651% |
| Biovica International AB (publ) | 133.72 Million SEK | 94.575% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 63.345% |
| AcouSort AB (publ) | 25.87 Million SEK | 71.966% |
| Abliva AB (publ) | 27.86 Million SEK | 73.968% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 96.251% |
| 2cureX AB (publ) | 36.51 Million SEK | 80.136% |
| I-Tech AB | 40.14 Million SEK | 81.932% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 99.156% |
| Cyxone AB (publ) | 28.21 Million SEK | 74.289% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 93.367% |
| Biosergen AB | 26.8 Million SEK | 72.942% |
| Nanologica AB (publ) | 69.88 Million SEK | 89.62% |
| SynAct Pharma AB | 224.49 Million SEK | 96.769% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 83.579% |
| BioInvent International AB (publ) | 441.4 Million SEK | 98.357% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 69.717% |
| Alzinova AB (publ) | 36.39 Million SEK | 80.069% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 97.496% |
| Pila Pharma AB (publ) | 7.85 Million SEK | 7.666% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 93.46% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | 50.653% |